Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities: 2015-2016

Historic Preferred Stock Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 2 years, with Dec 2016 value amounting to $77.0 million.

  • Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities rose 26.50% to $77.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $77.0 million, marking a year-over-year increase of 26.50%. This contributed to the annual value of $77.0 million for FY2016, which is 26.50% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Preferred Stock Liabilities stood at $77.0 million for FY2016, which was up 26.50% from $60.9 million recorded in FY2015.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities peaked at $77.0 million during FY2016, and registered a low of $60.9 million during FY2015.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $68.9 million (2015), whereas its average is $68.9 million.
  • Data for Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities shows a peak YoY rose of 26.50% (in 2016) over the last 5 years.
  • Over the past 2 years, Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities (Yearly) stood at $60.9 million in 2015, then grew by 26.50% to $77.0 million in 2016.